Aclaris Therapts (ACRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
Sales | 2,766 | 2,398 | 17,570 | 9,282 | 1,869 |
Cost of Goods | 1,909 | 1,840 | 6,428 | 8,192 | 1,592 |
Gross Profit | 857 | 558 | 11,142 | 1,090 | 277 |
Operating Expenses | 14,620 | 20,329 | 15,617 | 32,859 | 32,684 |
Operating Income | -12,854 | -18,931 | -4,047 | -31,577 | -31,815 |
Other Income | 1,868 | 1,990 | 2,189 | 2,316 | 2,246 |
Pre-tax Income | -10,986 | -16,941 | -1,858 | -29,261 | -29,569 |
Net Income Continuous | -10,986 | -16,941 | -1,491 | -29,261 | -29,569 |
Net Income | $-10,986 | $-16,941 | $-1,491 | $-29,261 | $-29,569 |
EPS Basic Total Ops | -0.15 | -0.24 | -0.02 | -0.41 | -0.42 |
EPS Basic Continuous Ops | -0.15 | -0.24 | -0.01 | -0.41 | -0.42 |
EPS Diluted Total Ops | -0.15 | -0.24 | -0.02 | -0.41 | -0.42 |
EPS Diluted Continuous Ops | -0.15 | -0.24 | -0.01 | -0.41 | -0.42 |
EPS Diluted Before Non-Recurring Items | -0.15 | -0.24 | -0.30 | -0.41 | -0.42 |
EBITDA(a) | $-12,612 | $-18,688 | $-3,819 | $-31,358 | $-31,597 |